**Amber N. Pepper, M.D.**

**CONTACT INFORMATION**

University of South Florida Asthma, Allergy, and Immunology Clinical Research Unit

13801 Bruce B. Downs Blvd., Suite 505

Tampa, FL 33613

Phone: (813) 631-4024, Ext. 200

21-JUL-2022

Fax: (813) 631-4030

University of South Florida Morsani College of Medicine, Division of Allergy and Immunology

c/o James A. Haley VA Hospital

13000 Bruce B. Downs. Blvd. (111D)

Tampa, FL 33612

Phone: (813) 972-7631

Fax: (813) 910-4041

Allergy, Asthma & Immunology Associates of Tampa Bay (AllergyTampa.com)

13801 Bruce B. Downs Blvd., Suite 502

Tampa, FL 33613

Phone: (813) 971-9743

Fax: (813) 558-9421

Website: allergytampa.com

**Academic email:** apepper1@usf.edu

**EDUCATION**

**Doctor of Medicine** August 2009 – May 2013University of South Florida Morsani College of Medicine, Tampa, FL Class rank: 1/107

Research Scholarly Concentration, AOA Junior Inductee

**Bachelor of Science in Integrative Biology** August 2005 – May 2009 University of Florida, Gainesville, FLGPA: 4.00/4.00

**POSTGRADUATE TRAINING**

**Allergy and Immunology Fellowship** July 2016 – June 2018

University of South Florida 2nd Year Chief Fellow

13801 Bruce B. Downs Blvd., Suite 505

Tampa, FL 33613

Phone: (813) 631-4024, Ext. 200

**Internal Medicine Residency** July 2013 – June 2016

University of South Florida3rd Year Chief Resident

17 Davis Blvd., Suite 308

Tampa, FL 33606

Phone: (813) 259-0697

**LICENSES AND CERTIFICATIONS**

**State Licenses:**

Florida Medical License: ME 126769 January 2016 – Present

**Certifications:**

American Board of Allergy and Immunology November 2018 – Present

American Board of Internal Medicine October 2016 – Present

BLS and ACLS Certified through 12/2022

**PROFESSIONAL SOCIETY MEMBERSHIPS**

Florida Allergy, Asthma, and Immunology Society May 2019 – Present

American Academy of Allergy, Asthma, and Immunology, Fellow July 2016 – Present

American College of Allergy, Asthma, and Immunology, FellowJuly 2016 – Present

**HOSPITAL AFFILIATIONS**

Tampa General Hospital, Tampa, FL August 2018 – Present

James A. Haley VA Hospital, Tampa, FL October 2018 – Present

Moffitt Cancer Center, Tampa, FL October 2018 – Present

**ACADEMIC APPOINTMENTS**

**Associate Director** Tampa, FL

University of South Florida Asthma, Allergy, and Immunology Clinical Research Unit January 2019 – Present

**Assistant Professor of Medicine and Pediatrics** Tampa, FL

University of South Florida August 2018 – Present

Department of Internal Medicine, Division of Allergy and Immunology

**Primary Investigator and Director** Tampa, FL

Food Allergy Research and Education (FARE) Clinical Research Center of Distinction June 2020 - Present

University of South Florida, Department of Internal Medicine, Division of Allergy and Immunology

**WORK EXPERIENCE**

**Allergy, Asthma & Immunology Associates of Tampa Bay (AllergyTampa.com)** Tampa, FL

USF-affiliated clinical practice August 2018 – Present

**SCHOLARLY ACTIVITY**

1. **Current Grants**

**Agency: Florida High Tech Corridor Counil’s Matching Grants Research Program**

**I.D.#: FHT 20-05 Molekule**

**Title: “A Placebo-controlled Trial of the Molekule Air Purifier in the Treatment of Pet Allergy”**

**P.I.: Amber N. Pepper, MD**

**Total funds for project period: $93,386**

**Project period: 09/2019 – 06/2023**

**PUBLISHED BIBLIOGRAPHY**

**Peer-Reviewed Publications**

1. Georas SN, Wright RJ, Ivanova A, **PrecISE Study Team**, et al. The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: An overview of Network organization, procedures, and interventions. J Allergy Clin Immunol. 2022;149(2):488-516.e9.
2. Westermann-Clark E, **Pepper AN**, Lockey RF. Anaphylaxis: Access to Epinephrine in Outpatient Setting. *Immunol Allergy Clin North Am*. 2022;42(1):175-186.
3. **Pepper AN**, Sriaroon P, Casale TB. Emerging developments in the forefront of peanut oral immunotherapy. *Curr Opin Allergy Clin Immunol.* 2021; 21(3):263-268.
4. **Pepper AN**, Hanania NA, Humbert M, Casale TB. How to assess effectiveness of biologics for asthma and what steps to take when there is not benefit. *J Allergy Clin Immunol Pract*. 2021; 9(3): 1081-8.
5. **Pepper AN**, Sriaroon PS, Glaum MC. Food Allergy Primer: Additives and preservatives: Role in food allergy. *J Food Allergy*. 2020;2(1): 119-123. doi: 10.2500/jfa.2020.2.200014.
6. **Pepper AN**, Assa'ad A, Blaiss M, Brown E, Chinthrajah S, Ciaccio C, et al. Consensus Report from the Food Allergy Research and Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit. *J Allergy Clin Immunol*. 2020; 146(2):244-249
7. **Pepper AN**, Bulkhi A, Smith CR, Collis M, Bergmann KC, Zuberbier T, Casale TB. Effects Of Exposure To New Car Interiors In Patients With Asthma And Allergic Rhinitis. *Allergy Rhinol (Providence)*. 2018; 9: 1-4.
8. Westermann-Clark E, **Pepper AN**, Lockey RF. Economic considerations in the treatment of systemic allergic reactions*. J Asthma Allergy*. 2018; 11:153-158.
9. **Pepper AN**, Ledford DK. Nasal and Ocular Challenges. *J Allergy Clin Immunol*. 2018;141(5):1570-1577.
10. Saco TV, **Pepper A**, Casale TB. Uses of biologics in allergic diseases: What to choose and when. *Ann Allergy Asthma Immunol*. 2018;120(4):357-366.
11. **Pepper AN**, Renz H, Casale TB, Garn H. Biologic Therapy and Novel Molecular Targets of Severe Asthma. *J Allergy Clin Immunol Pract.* 2017; 5(4):909–916.
12. Chen J, Zhou Y, Zhang L, Wang Y, **Pepper AN**, Cho SH, et al. Individualized Treatment of Allergic Rhinitis According to Nasal Cytology. *Allergy Asthma Immunol Res*. 2017; 9(5):403-409.
13. Saco TV, **Pepper AN**, Lockey RF. Benralizumab for the Treatment of Asthma. *Expert Rev Clin Immunol.* 2017;13(5):405-413.
14. **Pepper AN**, Westermann-Clark E, Lockey RF. The high cost of epinephrine autoinjectors and possible alternatives*. J Allergy Clin Immunol Pract.* 2017; 5(3):665-668.
15. **Pepper AN**, Calderón MA, Casale TB. Sublingual Immunotherapy for the Polyallergic Patient. *J Allergy Clin Immunol Pract*. 2017: 5(1):41-45.
16. **Pepper AN**, Cooke A, Livingston L, Lockey RF. Asthma and chronic obstructive pulmonary disease inhalers: techniques for proper use. *Allergy Asthma Proc*. 2016; 37(4):279-90.
17. Westermann-Clark E, **Pepper AN**, Talreja N, Lockey RF. Debunking myths about "allergy" to radiocontrast media in an academic institution. *Postgrad Med.* 2015; 127(3):295-300.
18. **Pepper AN**, Valenzuela MO, Oller KL. Aortoduodenal Fistula in a Patient on Intravitreal Bevacizumab Injections: A Case Report. *Am J Ther.* 2015; 22(3):e75-6.
19. **Pepper AN**, Talreja N, Cowan GM, Glaum MC and Lockey RF. Lymphopenia Induced by Etanercept. *Ann Allergy Asthma Immunol*. 2014; 112(3):262-3.

**Book Chapters**

1. Tolliver S, **Pepper AN**, Pothiawala S, and Silverberg NB. (2021). Pediatric Psoriasis and Therapy. In JM Weinberg and M Lebwohl (Eds.) *Advances in Psoriasis*. (pp. 311-342). Switzerland: Springer Nature.
2. **Pepper AN**, Ledford DK. (2016). Allergic Rhinitis: Diagnosis and Treatment. In Mahmoudi M (Ed.) *Allergy and Asthma: Practical Diagnosis and Management, 2nd edition*. (pp. 63-85). Switzerland: Springer International Publishing.
3. **Pepper AN**, Pothiawala S, and Silverberg NB. (2014). Pediatric Psoriasis and Therapy. In JM Weinberg and M Lebwohl (Eds.) *Advances in Psoriasis: A Multisystemic Guide*. (pp. 253-276). London: Springer.

**Abstracts and Poster Presentations**

1. Shepard KV, **Pepper AN**, Ledford DK. No Fun In Fungi: A Case of Allergic Fungal Rhinosinusitis. American College of Allergy, Asthma, and Immunology Annual Scientific Meeting in Seattle, WA on November 16, 2018.
2. **Pepper AN**, Bulkhi A, Smith CR, Collis M, Zuberbier T, Casale TB. Effects Of Exposure To New Car Interiors On Patients With Asthma And Allergic Rhinitis. American Academy of Allergy, Asthma & Immunology Annual Meeting in Orlando, FL on March 5, 2018.
3. Hudey S, **Pepper AN**, Wong K, Glaum M, Lockey RF. Systemic Mastocytosis Masquerading as Eosinophilic Gastroenteritis. American Academy of Allergy, Asthma & Immunology Annual Meeting in Orlando, FL on March 2, 2018.
4. **Pepper AN**, Ledford DK, Lockey RF. Angioedema Vanishing Into Thin Air. USF Health Research Day in Tampa, FL on February 24, 2018.
5. **Pepper AN**, Ledford DK, Lockey RF. Angioedema Vanishing Into Thin Air. American College of Allergy, Asthma, and Immunology Annual Scientific Meeting in Boston, MA on October 27, 2017.
6. **Pepper AN**, Ricketti PA, Glaum MC, Lockey RF. Hypogammaglobulinemia in a Patient with Stevens-Johnson Syndrome and Follicular Lymphoma. American College of Allergy, Asthma, and Immunology Annual Scientific Meeting in San Francisco, CA on November 11, 2016.
7. **Pepper AN**, Westermann-Clark E, Talreja N, and Lockey RF. Rectifying Misconceptions About Shellfish Allergy and Iodine “Allergy” In An Academic Institution. American Academy of Allergy, Asthma & Immunology Annual Meeting in San Diego, CA on March 4, 2014.
8. **Pepper AN**, Westermann-Clark E, Talreja N, and Lockey RF. Radiocontrast Media Reactions: Fact Versus Fiction. American College of Allergy, Asthma & Immunology Annual Scientific Meeting in Baltimore, MD on November 9-10, 2013.
9. Chuong FS, **Nardandrea A**, Silva CP, and Plosker S. Letrozole induced ovulation and pregnancies in anovulatory clomiphene citrate-resistant women. American Society of Reproductive Medicine Annual Meeting in San Diego, CA on October 23, 2012.
10. **Nardandrea A** and Plosker S. Efficacy of an aromatase inhibitor in achieving ovulation and pregnancy in clomiphene citrate-resistant women. USF Health Research Day in Tampa, FL on February 25, 2011.

**Oral Abstracts/Presentations**

1. **Pepper AN**, Lockey RF, Sriaroon P. Absent B cells and Hypogammaglobulinemia in an Adolescent with Granulomatosis with Polyangiitis. American Academy of Allergy, Asthma & Immunology Annual Meeting in Atlanta, GA on March 4, 2017.

**Other Publications and Activity**

1. **Pepper AN**, Lockey RF.Angioedema: Two Kinds, Different Outcomes. *The Bulletin of the Hillsborough County Medical Association*. 2018; 64:22-23.
2. **Pepper AN**, Updegraff A, and Lockey RF. (2015, July). Fatigue and generalized pruritus. World Allergy Organization. Available at: http://www.worldallergy.org/interactive\_case\_reviews.
3. **Pepper AN**, Salim N, and Lockey RF. (2014, April). Recurrent sinopulmonary infections. World Allergy Organization. Available at: http://www.worldallergy.org/interactive\_case\_reviews.
4. **Pepper AN**, Aljubran SA, and Lockey RF. (2013, May). Recurrent attacks of anaphylaxis. World Allergy Organization. Available at: http://www.worldallergy.org/interactive\_case\_reviews.

Manuscript reviewer for PLOS ONE, the Journal of Allergy and Clinical Immunology: In Practice, and USF IMPACT

**CLINICAL RESEARCH**

**USF Asthma, Allergy, and Immunology Clinical Research Unit** July 2016 – Present

Faculty Advisor: Thomas B. Casale, MD

Principal Investigator

1. Novartis (CQGE031G12301): A 52-week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients with peanut allergy
2. Gilead GS-US-556-5960: A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Tolerability of Tirabrutinib (BTK inhibitor) in Subjects with Antihistamine-Resistant Chronic Spontaneous Urticaria.
3. Regeneron R668-AD-1539B: A phase 2/3 study to evaluate the safety, pharmacokinetics, and efficacy of dupilumab in participants 6 months to less than 6 years of age with moderate-to-severe atopic dermatitis
4. Regeneron R668-AD-1434: An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients ≥6 months to <18 years of age with atopic dermatitis
5. Pfizer B7451015: A phase 3 study to Evaluate Efficacy and Safety of PF-04965842 (abrocitinib; JAK1 inhibitor) With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND)
6. Molekule: Industry-sponsored prospective, blinded, proof of concept study assessing air purifier effects on subjective and objective measures of asthma and allergic rhinitis in pet-sensitive subjects
7. Regeneron R3500-AD-1798; Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

Sub-Investigator:

1. ARS Pharmaceuticals (EPI-A01): A phase 2, single-dose, randomized, active and placebo controlled, cross-over study of the safety and efficacy of intranasal epinephrine after administration of ARS-1 or albuterol in subjects with persistent asthma
2. Alladapt (ADP101): An Open-Label Extension Study Evaluating the Safety and Efficacy of ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults (The Encore Study)
3. A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of Chronic Spontaneous Urticaria (CSU) in adolescents and adults inadequately controlled with H1-antihistamines
4. Master protocol of two randomized, double-blind, placebo-controlled, multi-center, parallel-group studies of dupilumab in patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite the use of H1 antihistamine treatment in patients naïve to omalizumab and in patients who are intolerant or incomplete responders to omalizumab--EFC16461
5. Mercedes: Evaluation of mucous membrane tolerability of vehicle components and their manufacturing materials

A prospective study evaluating mucous membrane tolerability of vehicle components and manufacturing materials in subjects with asthma and allergic rhinitis - Presented abstract and wrote (first author) manuscript published in a peer-reviewed journal

1. Open-label extension study of omalizumab in patients with chronic rhinosinusitis with nasal polyps, WA40169
2. A phase 2/3 study investigating the pharmacokinetics, safety, and efficacy of dupilumab in patients aged ≥6 months to <6 years with severe atopic dermatitis, R668-AD-1539
3. A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab administered concomitantly with topical corticosteroids in patients, ≥6 years to <12 years of age, with severe atopic dermatitis, R668-AD-1652
4. Patient empowered strategy to reduce asthma morbidity in highly impacted populations (PREPARE)
5. A phase 3 randomized withdrawal, double-blind, placebo-controlled, multi-center study investigating the efficacy and safety of PF-04965842 in subjects aged 12 years and over, with moderate to severe atopic dermatitis with the option of rescue treatment in flaring subjects, B7451014
6. Chronic refractory cough cohort study (COCO)
7. Losartan effects on emphysema progression (LEEP)
8. Parental response using a daily digital diary to capture respiratory symptoms in young children with recurrent respiratory tract illnesses (American Lung Association [ALA] Novel Digital Diary [ANDDI])
9. Asthma BMI baseline study (ABBS)
10. A multi-center, randomized, double-blind, active and placebo-controlled study to investigate the efficacy and safety of ligelizumab (QGE031) in the treatment of chronic spontaneous urticaria (CSU) in adolescents and adults inadequately controlled with h1-antihistamines, CQGE031C2302
11. A randomized, subject- and investigator-blinded, placebo-controlled, multi-center, multiple dose study to assess the efficacy and safety of CJM112 in patients with inadequately controlled moderate to severe asthma, CCJM112X2204
12. A phase 2, multicenter, randomized, double-blind, placebo-controlled pilot and dose-ranging study of gdc-0853 in patients with refractory chronic spontaneous urticaria (CSU), GS39684
13. A phase 2 open-label extension study to evaluate the long-term safety and efficacy of fenebrutinib in patients previously enrolled in a fenebrutinib chronic spontaneous urticaria study, GS40868
14. Help study extension: an open-label study to evaluate the long-term safety and efficacy of DX-2930 for prevention against acute attacks of hereditary angioedema (HAE), DX-2930-04
15. Real-world ar101 market-supporting experience study in peanut-allergic children, active treatment arm open-label extension study (RAMSES OLE), ARC011
16. A multicenter, open-label, long-term safety study of AR101 characterized oral desensitization immunotherapy in subjects who participated in a prior AR101 study, ARC008
17. Peanut allergy oral immunotherapy study of AR101 for desensitization in children and adults (PALISADE) follow-on study, ARC004
18. Real-world AR101 market-supporting experience study in peanut-allergic children ages 4 to 17 years (RAMSES), ARC007
19. A phase 2, multicenter, randomized, double-blind, placebo-controlled study in pediatric subjects with peanut allergy to evaluate the efficacy and safety of dupilumab as adjunct to AR101-CODIT (peanut oral immunotherapy), R668-ALG-16114
20. A study to evaluate the efficacy and safety of dupilumab monotherapy in pediatric patients with peanut allergy, R668-ALG-1702
21. A phase 3, randomized, multicenter, double-blind, placebo-controlled clinical trial of omalizumab in patients with chronic rhinosinusitis with nasal polyps, GA39855
22. A double-blind, randomized, placebo-controlled study of the efficacy and safety of three doses of orvepitant in subjects with chronic refractory cough, VOLCANO-2

**USF Division of Allergy and Immunology**  November 2012 – April 2015

Faculty Advisor: Richard F. Lockey, MD

Sub-investigator and author in a prospective survey study examining misconceptions about reactions to contrast media, shellfish, and iodine - Prepared the protocol, completed the IRB application, collected data, drafted and presented abstracts and posters, and helped write manuscript published in a peer-reviewed journal

**USF IVF and Department of Reproductive Endocrinology**  January 2010 – December 2012

Faculty Advisor: Shayne Plosker, MD

Sub-investigator in a retrospective analysis examining the effectiveness of aromatase inhibitors on ovulation induction

**BASIC SCIENCE RESEARCH**

**University of Florida Department of Behavioral Neuroscience** May 2007 – December 2008

Faculty Advisor: Neil E. Rowland, PhD

Worked with mice and rats exploring the effects of genetics on calorie intake and nicotine consumption

**LEADERSHIP EXPERIENCE**

**Co-Director, USF Symposium Update in Allergy and Immunology** February 2019 – March 2020

 Work with director to facilitate lecturers, sponsorships, accreditation, and attendance at symposium

**2nd Year Allergy and Immunology Chief Fellow** May 2017 – June 2018

Functioned as an advocate for fellows and worked with faculty to improve the fellowship program

**3rd Year Internal Medicine Chief Resident, Ambulatory Sites** May 2015 – June 2016

Functioned as an advocate for residents and worked with faculty to improve the residency program

**USF Internal Medicine Residency Jeopardy Team Captain** October 2013 – June 2016

Participated in and lead medical knowledge competitions

**USF Morsani College of Medicine Student Council Class of 2013 Secretary** September 2009 – May 2013

Recorded minutes at all Class of 2013 officer meetings and distributed announcements weekly

**TEACHING EXPERIENCE**

**USF Allergy and Immunology Fellowship Board Review Sessions** September 2020 – Present

Lead weekly ABAI board preparation sessions with the fellows

**Doctoring Clinical Experience (DCE) Preceptor** August 2019 – Present

 Teach clinical skills to 1st and 2nd year medical students during clinic in a hands-on manner

**USF Morsani College of Medicine Doctoring 2 Preceptor** July 2012 – May 2013; August 2018 – April 2019

 Taught clinical reasoning, physical exam, professionalism, and ethics to 2nd year medical students

**QUALITY IMPROVEMENT**

**Penicillin desensitization order set**  July 2017 – June 2018

 Worked with pharmacy/nursing to develop a penicillin desensitization order set at Tampa General Hospital

**Electronic document storage for USF Allergy and Immunology fellowship** July 2017 – June 2018

 As chief fellow, set up electronic storage for important fellowship documents for continuous online access

**Biologic therapy protocol** October 2016 – June 2017

 Developed a protocol for administration of biologic therapies in allergy clinic at James A. Haley VA Hospital

**Quick orders for allergy/immunology labs** July 2016 – June 2017

 Created quick orders at USF Morsani clinic for difficult to find labs for fellows and faculty

**SERVICE AND COMMITTEES**

**USF Division of Allergy and Immunology Program Evaluation Committee** May 2019 - Present

Member, evaluate fellowship program and implement changes to enhance training experience

**USF Division of Allergy and Immunology Clinical Competency Committee** May 2019 - PresentMember, provide and review feedback of clinical training for fellows

**WOC Volunteer Physician at James A. Haley VA Hospital** October 2018 – Present

 Provide medical services to veterans and supervision of medical trainees

**BRIDGE and Judeo Christian Clinics** February 2010 – June 2016

Provided much-needed medical care for the underserved of Tampa Bay

**Project World Health** September 2009 – August 2010

Raised funds and provided medical care to the people of the Jarabacoa region of the Dominican Republic

**HONORS AND AWARDS**

**TAMPA magazine “Top Doctors” winner**  2019, 2020, 2021, 2022

**Food Allergy Research and Education Clinical Research Center of Distinction**  2020

**USF Internal Medicine Chairman’s Leadership Award**  2016

Awarded for excellence in balancing competing demands while improving the residency program

**American College of Physicians Florida Chapter Chief Resident Award**  2016

**USF Internal Medicine Resident of the Month**  2014

**AAAAI Chrysalis Project** 2014

**Roy H. Behnke, MD Award** 2013

**College of Medicine Dean’s Award** 2013

Awarded to the student first in their class after 4 years of medical school

**Academic Excellence Award**  2013

**Alpha Omega Alpha Honor Medical Society** 2012

Junior inductee, Gamma Chapter

**D.L. Smith Charter Class Scholarship** 2012

Awarded to the student first in their class after 3 years of medical school

**Commendation for Clinical Excellence**  2012

**Martin and Ruth Silbiger Endowed Scholarship**  2011

Awarded to the student first in their class after 2 years of medical school

**USF Health Morsani College of Medicine Merit Scholarship** 2011

**USF Health Morsani Office of Educational Development Summer Research Stipend** 2010